Evidence map›Paper›PMID 41691371›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies.

Viktor T Lemgart, Andrew J Sawyer, William Kuhlman, Aaron P Griset, Mir M Ali, Allison Caron, Dharini Shah, Tiffany Le, Laura Strauss, Jing Jiao and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Frontiers in immunology · 2026
    Review
  8. Targeted delivery platforms forFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Viktor T LemgartOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Andrew J SawyerOncology Research, Sanofi, Cambridge, MA 02141, USA.
William KuhlmanOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Aaron P GrisetOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Mir M AliOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Allison CaronOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Dharini ShahOncology Research, Sanofi, Cambridge, MA 02141, USA.
Tiffany LeGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Laura StraussOncology Pharmacology, Sanofi, Cambridge, MA 02141, USA.
Jing JiaoOncology Pharmacology, Sanofi, Cambridge, MA 02141, USA.
Francis J DescampsLMR, Sanofi, 1831 Ghent, Belgium.
Sampa MaitiOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Michael T MonteOncology Research, Sanofi, Cambridge, MA 02141, USA.
Ralston AugspurgOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
Eyoung ShinOncology Research, Sanofi, Cambridge, MA 02141, USA.
Ernesto LunaVaxDesign, Sanofi, Orlando, FL 32826, USA.
Pankaj AgrawalVaxDesign, Sanofi, Orlando, FL 32826, USA.
Jan PypeLMR, Sanofi, 1831 Ghent, Belgium.
Olga LihoradovaOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.
James CaoGlobal Discovery Pathology and Multimodal Imaging, Sanofi, Cambridge, MA 02141, USA.
Brandon QuidoOncology Pharmacology, Sanofi, Cambridge, MA 02141, USA.
Laura PowersOncology Pharmacology, Sanofi, Cambridge, MA 02141, USA.
Fazila NasimiGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Jacob ScantlandGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Kavana GirishGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Rasika D KundenGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Jennifer RichardsOncology Research, Sanofi, Cambridge, MA 02141, USA.
Samantha StewartGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Seunghee LeeGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Garry CuneoCytek Biosciences, Fremont, CA 94538, USA.
Janina SchwartePMCB, Sanofi, Cambridge, MA 02141, USA.
Christian MuellerGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Christopher M BorgesGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Austin W BoeschOncology Research, Sanofi, Cambridge, MA 02141, USA.
Valeria R FantinOncology Research, Sanofi, Cambridge, MA 02141, USA.
Ulrik B NielsenOncology Research, Sanofi, Cambridge, MA 02141, USA.
Donald R ShafferOncology Research, Sanofi, Cambridge, MA 02141, USA. Electronic address: donald.shaffer@sanofi.com.
Daryl C DrummondOncology Research, Sanofi, Cambridge, MA 02141, USA; Genomic Medicine Unit, Sanofi, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ex vivo chimeric antigen receptor (CAR) T cell therapy has proven successful in patients with B cell hematologic malignancies. However, current approaches are limited by the requirement for personal manufacturing processes and by barriers such as limited efficacy against solid tumors, treatment-associated toxicities, insufficient CAR-T cell trafficking to the tumor microenvironment, on-target off-tumor effects, and tumor antigen escape. Here, we describe a novel delivery platform that overcomes many of these barriers by employing targeted lipid nanoparticles (LNPs) to reprogram circulating human T cells in vivo. Using a NANOBODYVHH (variable heavy domain of heavy chain)-based targeting moiety, we deliver mRNA encoding a novel CD22 CAR specifically to CD8

Indexed as

CD8-Positive T-LymphocytesHematologic NeoplasmsImmunotherapy, AdoptiveNanoparticlesReceptors, Chimeric AntigenRNA, MessengerSialic Acid Binding Ig-like Lectin 2AnimalsCell Line, TumorDisease Models, AnimalHumansLipidsLiposomesMiceReceptors, Antigen, T-CellXenograft Model Antitumor AssaysCD22 protein, humanLipid NanoparticlesLipidsLiposomesReceptors, Antigen, T-CellReceptors, Chimeric AntigenRNA, MessengerSialic Acid Binding Ig-like Lectin 2CAR-TCD22CD8(+) T cellsin vivo reprogramminglipid nanoparticleLNPmRNA

Identifiers

PMID41691371
PMCPMC13154270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.